Author:
Heijns Joan B.,van der Burg Maria E. L.,van Gelder Teun,Fieren Marien W. J. A.,de Bruijn Peter,van der Gaast Ate,Loos Walter J.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference37 articles.
1. Balat O, Kudelka AP, Edwards CL, Verschraegen C, Mante R, Kavanagh JJ (1996) A case report of paclitaxel administered to a patient with platinum-refractory ovarian cancer on long-term hemodialysis. Eur J Gynaecol Oncol 17:232–233
2. Cadron I, Leunen K, Amant F, Van Gorp T, Neven P, Vergote I (2007) The “Leuven” dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer. Gynecol Oncol 106:354–361
3. Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756
4. Chatelut E, Rostaing L, Gualano V, Vissac T, De Forni M, Ton-That H, Suc JM, Houin G, Canal P (1994) Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency. Nephron 66:157–161
5. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献